Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
C. Boch, J. Kollmeier, A. Roth, D. Misch, T. Weiß, A. Streubel, T. Mairinger, T. T. Bauer (Berlin, Germany). The prognostic value of KRAS mutation according to the gene's. Eur Respir J 2014; 44: Suppl. 58, 511

Member's Comments

No comment yet.

Related content which might interest you: Prognostic value of EGFR mutation in NSCLC in surgical stage Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The value of miR221 and miR222 as a biomarker in non small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Serum IL-33 as a diagnostic and prognostic marker in non- small cell lung cancer Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Gene expression of EGFR, MINA53,MEN1 and MTOR in NSCLCs Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Methilation status in EBUS-NA samples of lung cancer Source: International Congress 2014 – Improving diagnosis of thoracic tumours Year: 2014 Integrative analysis of DNA copy number in metastatic NSCLC identifies drug sensitivity to Afatinib Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Polymorphism of HLA-G gene promotor in patients with non small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Differences in expression and prognostic values of p16(ink) and VEGF in squamous and adenocarcinoma of the lung Source: International Congress 2014 – Pathology and prognostic factors of thoracic tumours Year: 2014 Metabolomic analysis of serum samples from patients with lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Metabolic signatures associated with lung cancer using serum samples. Influence of hemolysis Source: International Congress 2014 – Biology and pathology of thoracic tumours Year: 2014 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Lung cancer after lymphoma: Disease characteristics, detection methods and clinical outcome Source: Annual Congress 2013 –Other thoracic tumours, particular circumstances and rare cases Year: 2013 Relationship between risk factors for lung cancer and tumor size Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Frequency and type of EGFR mutations in patients with adenocarcinoma of the lung Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013 EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014 Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015 Clinical characteristics of 32 patients with BRAF V600E-mutated lung adenocarcinoma Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Second primary lung cancer in squamous NSCLC patients: The Nancy Biobank's database Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014 Symptom-to-treatment intervals in lung cancer Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014